Envisagenics and Boehringer Ingelheim entered a multi year research and option agreement to discover and validate tumor specific targets derived from alternative RNA splicing. Boehringer may develop selected targets using antibody drug conjugates, T…
Pharming reported positive topline data from 13 participants with genetically defined primary immunodeficiencies linked to PI3K signaling. In the open label within patient dose escalation study, leniolisib produced a mean 26.4 percent spleen volume…
Roche reported that once weekly enicepatide met both primary endpoints in the randomized Phase 2 CT 388 104 study. At 24 mg, mean HbA1c fell 2.65 percentage points and body weight fell 15.5 percent…
Shanghai RAAS disclosed on 17 September that SR604 entered a single arm multicenter Phase 3 study for prophylaxis in hemophilia A or B patients with or without inhibitors. The registered dose is 0.4 mg…
A peer reviewed Blood Cancer Discovery study reported that all 11 adults and children with relapsed or refractory B cell acute lymphoblastic leukemia achieved complete remission by Day 28 after CART2219.1, and 91 percent…
Vertex reported Phase 2b AMPLIFIED data in 41 people with APOL1 mediated kidney disease. Inaxaplin 45 mg once daily on top of standard care reduced urine albumin to creatinine ratio by 42.7 percent at…
Viking reported that participants switching from weekly VK2735 induction to every other week dosing maintained an average 90 percent of prior weight loss over 12 weeks, while monthly dosing maintained 85 percent versus 61…
Amgen reported that the approximately 621-participant OASIZ 301 trial met its Week 48 primary endpoint in adults with moderate-to-severe systemic Sjogren disease. Dazodalibep produced a statistically significant and company-characterized clinically meaningful improvement in ESSDAI,…
Asieris disclosed that Chief Scientific Officer Ningshu Liu resigned for personal reasons and will hold no continuing role. The filing was dated September 19, roughly eight months after her appointment to lead early discovery…
Hangzhou Baicreat reported that China’s NMPA Center for Drug Evaluation permitted clinical testing of BCR-0008, an oral STAT6-targeted PROTAC intended initially for atopic dermatitis and asthma. The milestone moves targeted protein degradation into a…
